GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Short-Term Debt

Radiopharm Theranostics (ASX:RAD) Short-Term Debt : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Short-Term Debt?

Radiopharm Theranostics's Short-Term Debt for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Radiopharm Theranostics Short-Term Debt Historical Data

The historical data trend for Radiopharm Theranostics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Short-Term Debt Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24
Short-Term Debt
- - -

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Short-Term Debt Get a 7-Day Free Trial - - - - -

Radiopharm Theranostics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Radiopharm Theranostics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Radiopharm Theranostics Headlines

No Headlines